Physician profile
Iman Khan
NPI 1356902498
$513.61
in general payments reported to CMS, 2019-2025
11 companies · $444 in 2025
The $444 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.61 · 2024: $53.04 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $90.23 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $81.27 | 2024-2025 | Aptima, Myosure Tissue Removal Device, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Millicent US INC | $75.97 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Biogen, INC. | $59.54 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $51.29 | 2025 | Veozah |
| Coopersurgical, INC. | $43.11 | 2025 | Endosee, Paragard T 380a |
| Channel Medsystems, INC. | $28.70 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.04 | 2025 | |
| Mayne Pharma Commercial LLC | $22.70 | 2025 | |
| Novo Nordisk INC | $17.15 | 2025 | Wegovy |
| Boston Scientific Corporation | $16.61 | 2023 | Upsylon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iman Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.